Kazuki Nozawa, MD· @kazuki_nozawa · X·· 1 天前评分70
正文 · 机器翻译
FOURLIGHT-1
#ESMO26
@antgiorda
在 CDK4/6i 治疗后，Atirmociclib + fulvestrant 相比研究者选择方案，显著改善了 HR+/HER2− 转移性乳腺癌患者的 PFS（9.4 vs 6.6 个月；HR 0.60）。CBR 更高（61.9% vs 46.0%），安全性可控，但 ≥3 级 AEs 更为常见。
191 浏览 · 1 赞 · 2 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Kazuki Nozawa, MD · x.com